Assuntos
Neoplasias Ósseas/história , Neoplasias Induzidas por Radiação/história , Sarcoma/história , Doenças Ósseas/história , Doenças Ósseas/radioterapia , Neoplasias Ósseas/etiologia , Neoplasias Ósseas/radioterapia , História do Século XX , Humanos , Radioterapia/efeitos adversos , Radioterapia/história , Sarcoma/etiologiaRESUMO
STUDY OBJECTIVE: To investigate the efficacy of adding butorphanol to bupivacaine administered in the caudal epidural space in children undergoing genitourinary (GU) procedures. DESIGN: Randomized, double-blinded, controlled study. SETTING: University affiliated pediatric hospital. PATIENTS: 200 ASA physical status I and II male patients between 6 months and 10 years of age. INTERVENTIONS: Patients were randomized to receive either 0.25% bupivacaine with 1:200,000 epinephrine alone (Group 1) or 0.25% bupivacaine with 1:200,000 epinephrine plus 30 micrograms/kg butorphanol (Group 2) administered via the caudal epidural space prior to surgical incision. MEASUREMENTS AND MAIN RESULTS: Patients were evaluated postoperatively until discharge. Measurements included requirement of additional analgesic, sedation, pain/ comfort scores, and a 24-hour analgesic follow-up. Significantly fewer patients in the butorphanol group required rescue morphine sulfate in the postanesthesia care unit (p < or = 0.001). The total number of morphine doses administered to Group 2 was significantly less than Group 1 (p < or = 0.001). 52% of patients in Group 1 compared with 28% in Group 2 required administration of additional analgesics following discharge from the hospital (p < or = 0.003), with 23% of Group 1 requiring a codeine compound compared with 8% in Group 2 (p < 0.03). CONCLUSIONS: The addition of 30 micrograms/kg butorphanol to 0.25% bupivacaine with epinephrine via the caudal epidural space is a safe, effective means to increase duration of analgesia following GU procedures.
Assuntos
Analgésicos Opioides , Anestesia Epidural , Anestésicos Locais , Bupivacaína , Butorfanol , Genitália/cirurgia , Procedimentos Cirúrgicos Ambulatórios , Analgésicos Opioides/administração & dosagem , Anestésicos Locais/administração & dosagem , Bupivacaína/administração & dosagem , Butorfanol/administração & dosagem , Criança , Pré-Escolar , Método Duplo-Cego , Epinefrina , Humanos , Lactente , Masculino , Medição da DorAssuntos
Varizes Esofágicas e Gástricas/complicações , Fístula/complicações , Embolização Terapêutica , Varizes Esofágicas e Gástricas/fisiopatologia , Varizes Esofágicas e Gástricas/terapia , Feminino , Humanos , Pessoa de Meia-Idade , Sistema Porta/fisiopatologia , Derivação Portossistêmica Transjugular Intra-Hepática , Veias Renais , Veia EsplênicaRESUMO
Sixty-six patients with well-documented osteogenic sarcomas arising in bones and soft tissues after exposure to x-rays, which represent approximately 5.5 percent of all osteogenic sarcomas registered since 1921 at this institution, were studied. These secondary sarcomas occurred in equal proportion in both sexes, with the sixth decade of life being the most common age. In 42 patients, the bone had been normal at the time of irradiation, whereas in 24, the radiation was directed against an osseous tumor or tumor-like lesion. The median latent period was 10.5 years in both groups, ranging from 3.5 to 33 years. The radiation varied from diagnostic quality to 1 MeV x-rays. The dose was variable, but none was less than 2000 rads. Postradiation osteogenic sarcomas most commonly arose in the bones of the pelvic and shoulder regions. Histologically, the sarcomas were mostly of the fibrous type (46%) and radiographically showed a destructive bone lesion with or without signs of radiation osteitis. The cumulative disease-free survival rate at 5 years was 17%, with a median survival estimate of 1 year.